Suppr超能文献

载有酮康唑的眼用前体脂质体凝胶:制剂、离体角膜渗透及体内研究

Ocular ketoconazole-loaded proniosomal gels: formulation, ex vivo corneal permeation and in vivo studies.

作者信息

Abdelbary Ghada A, Amin Maha M, Zakaria Mohamed Y

机构信息

a Department Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Cairo University , Cairo , Egypt and.

b Department Pharmaceutics and Industrial Pharmacy , Faculty of Pharmacy, Sinai University , Sinai , Egypt.

出版信息

Drug Deliv. 2017 Nov;24(1):309-319. doi: 10.1080/10717544.2016.1247928.

Abstract

CONTEXT

Vesicular drug carriers for ocular delivery have gained a real potential. Proniosomal gels as ocular drug carriers have been proven to be an effective way to improve bioavailability and patient compliance.

OBJECTIVE

Formulation and in vitro/ex vivo/in vivo characterization of ketoconazole (KET)-loaded proniosomal gels for the treatment of ocular keratitis.

MATERIALS AND METHODS

The effect of formulation variables; HLB value, type and concentration of non-ionic surfactants (Tweens, Spans, Brijs and Pluronics) with or without lecithin on the entrapment efficiency (EE%), vesicle size and in vitro KET release was evaluated. An ex vivo corneal permeation study to determine the level of KET in the external eye tissue of albino rabbits and an in vivo assessment of the level of KET in the aqueous humors were performed.

RESULTS AND DISCUSSION

In vivo evaluation showed an increase in bioavailability up to 20-folds from the optimum KET proniosomal gel formula in the aqueous humor compared to drug suspension (KET-SP). The selected formulae were composed of spans being hydrophobic suggesting the potential use of a more hydrophobic surfactant as Span during the formulation of formulae. Factors that stabilize the vesicle membrane and increase the entrapment efficiency of KET (namely low HLB, long alkyl chain, high phase transition temperature) slowed down the release profile.

CONCLUSIONS

Proniosomal gels as drug delivery carriers were proven to be a promising approach to increase corneal contact and permeation as well as retention time in the eye resulting in a sustained action and enhanced bioavailability.

摘要

背景

用于眼部给药的囊泡型药物载体已展现出真正的潜力。前体脂质体凝胶作为眼部药物载体已被证明是提高生物利用度和患者依从性的有效方法。

目的

制备用于治疗眼部角膜炎的酮康唑(KET)负载型前体脂质体凝胶,并进行体外/离体/体内表征。

材料与方法

评估配方变量;亲水亲油平衡值(HLB值)、有无卵磷脂时非离子表面活性剂(吐温、司盘、Brij系列和泊洛沙姆)的类型和浓度对包封率(EE%)、囊泡大小和酮康唑体外释放的影响。进行了一项离体角膜渗透研究,以确定白化兔眼外组织中的酮康唑水平,并对房水中的酮康唑水平进行了体内评估。

结果与讨论

体内评估显示,与药物混悬液(KET-SP)相比,最佳酮康唑前体脂质体凝胶配方在房水中的生物利用度提高了20倍。所选配方由疏水的司盘组成,这表明在配方制备过程中使用更疏水的表面活性剂如司盘具有潜在的用途。稳定囊泡膜并提高酮康唑包封率的因素(即低HLB值、长烷基链、高相变温度)减缓了释放曲线。

结论

前体脂质体凝胶作为药物递送载体被证明是一种有前景的方法,可增加角膜接触和渗透以及在眼内的停留时间,从而实现持续作用并提高生物利用度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0b50/8241068/ee4e2d8da4dc/IDRD_A_1247928_F0001_C.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验